News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Eisai Company, Ltd. Puts $200 Million into US Personalised Medicine Unit
January 31, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Eisai has formed a biotech start-up in the USA, H3 Biomedecines, which will focus on discovering and developing next-generation cancer drugs.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Layoff Tracker
Merck Continues Cuts With 204 Laid Off in New Jersey
November 18, 2025
·
86 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash
November 17, 2025
·
2 min read
·
Dan Samorodnitsky
Collaboration
Lilly Bets More Than $2.6B for South Korea Biotech’s Bispecific Antibody Platform
November 17, 2025
·
2 min read
·
Tristan Manalac
Funding
Artios Pushes Cancer Pipeline Forward With $115M Series D
November 17, 2025
·
1 min read
·
Tristan Manalac
